CASP3 and Hepatic steatosis: Furthermore, it downregulated the apoptotic executor, active caspase-3.<h4>Conclusions</h4>The CJO NEs have shown strong promise in lowering obesity-induced hepatic steatosis and mitigating cardiac and pancreatic injury via hypoglycemic, antidyslipidemic, cytoprotective, antioxidant, and antiapoptotic activities.